All In Biotech

NDA 019906 · Specgx LLC

Anafranil

Clomipramine Hydrochloride · Oral

NovelPriority review

Last checked: Nov 20, 2026Latest source record: May 10, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1989

Dec 29, 1989

Approved uses

1

Original approval plus efficacy supplements

Registered trials

24

4 Phase 3, 2 recruiting

FAERS reports

4,574

4,205 serious, 402 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of clomipramine hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and...

What it is approved for

From the label in effect Nov 26, 2024.

INDICATIONS AND USAGE Anafranil ™ (clomipramine hydrochloride) Capsules USP is indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). The obsessions or compulsions must cause marked distress, be time-consuming, or significantly interfere with social or occupational functioning, in order to meet the DSM-III-R (circa 1989) diagnosis of OCD. Obsessions are recurrent, persistent ideas, thoughts, images, or impulses that are ego-dystonic. Compulsions are repetitive, purposeful, and intentional behaviors performed in response to an obsession or in a stereotyped fashion, and are recognized by the person as excessive or unreasonable. The effectiveness of Anafranil for the treatment of OCD was demonstrated in multicenter, placebo-controlled, parallel-group studies, including two 10-week studies in adults and one 8-week study in children and adolescents 10 to 17 years of age. Patients in all studies had moderate-to-severe OCD (DSM-III), with mean baseline ratings on the Yale-Brown Obsessive Compulsive Scale (YBOCS) ranging from 26 to 28 and a mean baseline rating of 10 on the NIMH Clinical Global Obsessive Compulsive Scale (NIMH-OC). Patients taking CMI experienced a mean reduction of approximately 10 on the YBOCS, representing an average improvement on this scale of 35% to 42% among adults and 37% among children and adolescents. CMI-treated patients experienced a 3.5 unit decrement on the NIMH-OC. Patients on placebo showed no important clinical response on either scale. The maximum dose was 250 mg/day for most adults and 3 mg/kg/day (up to 200 mg) for all children and adolescents. The effectiveness of Anafranil for long-term use (i.e., for more than 10 weeks) has not been systematically evaluated in placebo-controlled...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • ANAFRANIL · CLOMIPRAMINE HYDROCHLORIDE 75MG · CAPSULE, ORAL · Prescription · TE AB
  • ANAFRANIL · CLOMIPRAMINE HYDROCHLORIDE 25MG · CAPSULE, ORAL · Prescription · TE AB
  • ANAFRANIL · CLOMIPRAMINE HYDROCHLORIDE 50MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Clomipramine" as an intervention, any sponsor and status, largest first.

All 24 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug interaction234
  • somnolence217
  • fall209
  • off label use200
  • tremor189
  • nausea182
  • coma180
  • suicide attempt177
  • intentional overdose176
  • drug ineffective173
  • anxiety167
  • confusional state166

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004168
2005121
2006118
2007139
2008156
2009153
2010161
2011192
2012180
2013169
2014199
2015221
2016257
2017261
2018290
2019304
2020291
2021190
2022206
2023248
2024210
2025169
2026170

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Anafranil (Clomipramine HCl)

2024 spending

$1.0M

Beneficiaries

42

224 claims

Per beneficiary

$24,711

$35.01 per unit

View as table
YearSpending
2020$1,390,951
2021$1,302,137
2022$1,373,335
2023$1,057,492
2024$1,037,850

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 625 on PubMed

Sponsor: Specgx LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.